Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood (2024) 143 (22): 2256–2269.

https://doi.org/10.1182/blood.2023021864

Published: 2024

Includes: Supplemental data

Journal Articles

Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment

Assaf Arie Barg, Tami Livnat, Gili Kenet

Blood (2024) 143 (15): 1455–1464.

https://doi.org/10.1182/blood.2023020721

Published: 2024

Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2024) 143 (14): 1355–1364.

https://doi.org/10.1182/blood.2023021832

Published: 2024

Includes: Supplemental data

Journal Articles

Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis

Shadan Lalezari, Rivka Carmiel, Ivan Budnik, Gili Kenet, Sarina Levy-Mendelovich

Blood (2023) 142 (Supplement 1): 5535.

https://doi.org/10.1182/blood-2023-184763

Published: 2023

Journal Articles

rAAV8-PC Gene Therapy for Severe Protein C Deficiency Using a Novel Murine Model

Sarina Levy-Mendelovich, Einat Avishai, Ben J Samelson-Jones, Rima Dardik, Tami barazani-Brutman, Yael Nisgav, Tami Livnat, Gili Kenet

Blood (2023) 142 (Supplement 1): 7119.

https://doi.org/10.1182/blood-2023-181140

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Anna Kiialainen, Steven Pipe, Karin Fijnvandraat, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Johannes Oldenburg, Maria Elisa Mancuso, Christophe Dhalluin, Michaela Lehle, Peter Collins

Blood (2023) 142 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2023-173015

Published: 2023

Journal Articles

Intravenous 3K3A-Activated Protein C Inhibits Murine Ocular Inflammation and Suppresses Ocular Choroidal Neovascularization

Tami Livnat, Yael Nisgav, José A Fernández, Ivan Budnik, Sarina Levy-Mendelovich, Dov Weinberger, Gili Kenet, John Griffin

Blood (2023) 142 (Supplement 1): 2602.

https://doi.org/10.1182/blood-2023-181533

Published: 2023

Journal Articles

Pediatric Splenic Infarcts - a 10-Year Retrospective Study

Evgeny Grishin, Michalle Soudack, Aaron Lubetsky, Sarina Levy-Mendelovich, Omri Cohen, Amos Toren, Bella Bielorai, Gili Kenet, Assaf Arie Barg

Blood (2023) 142 (Supplement 1): 2657.

https://doi.org/10.1182/blood-2023-181079

Published: 2023

Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat

Blood (2023) 142 (Supplement 1): 505.

https://doi.org/10.1182/blood-2023-177963

Published: 2023

Journal Articles

Pediatric Splanchnic Vein Thrombosis: Systematic Review and Meta-Analysis

Sarina Levy-Mendelovich, Shelly Soffer, Eyal Klang, Assaf Arie Barg, Walter Ageno, Gili Kenet, Omri Cohen

Blood (2022) 140 (Supplement 1): 5690–5691.

https://doi.org/10.1182/blood-2022-165236

Published: 2022

Journal Articles

Venous Thromboembolism in Children, Adolescents and Young Adults: Findings from the Riete Registry

Omri Cohen, Assaf Arie Barg, Ulrike Nowak-Göttl, Reina Valle, Lucia Mazzolai, Gregorio Tiberio, Sebastian Schellong, Andris Skride, Mª del Valle Morales, Manuel Monreal, Gili Kenet

Blood (2022) 140 (Supplement 1): 5692–5693.

https://doi.org/10.1182/blood-2022-159499

Published: 2022

Journal Articles

Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

Blood (2022) 140 (Supplement 1): 1899–1901.

https://doi.org/10.1182/blood-2022-158903

Published: 2022

Journal Articles

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Gili Kenet, Ampaiwan Chuansumrit, Tadashi Matsushita, Guy Young, Vandana Yadav, Marek Zak, Christoph Male

Blood (2022) 140 (Supplement 1): 2726–2727.

https://doi.org/10.1182/blood-2022-162331

Published: 2022

Journal Articles

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Gili Kenet, Beatrice Nolan, Tadashi Matsushita, Guy Young, Ting Quan, Viridiana Cano, Christian Sussebach, Shauna Andersson, Baisong Mei, Marion Afonso, Kaan Kavakli

Blood (2022) 140 (Supplement 1): 7977–7978.

https://doi.org/10.1182/blood-2022-167169

Published: 2022

Journal Articles

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

Blood (2022) 140 (Supplement 1): 457–459.

https://doi.org/10.1182/blood-2022-157264

Published: 2022

Journal Articles

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry

Konrad Van Der Zwet, Marloes de Kovel, Jayashree Motwani, Christel Van Geet, Beatrice Nolan, Heidi Glosli, Gili Kenet, Kathelijn Fischer

Blood (2022) 140 (Supplement 1): 8442–8443.

https://doi.org/10.1182/blood-2022-162181

Published: 2022

Journal Articles

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Alok Srivastava, Savita Rangarajan, Kaan Kavakli, Robert Klamroth, Gili Kenet, Liane Khoo, Chur-Woo You, Weiqun Xu, Niel Malan, Laurent Frenzel, Catherine N. Bagot, Oleksandra Stasyshyn, Chia-Yau Chang, Stacey Poloskey, Shauna Andersson, Zhiying Qiu, Baisong Mei, Steven W. Pipe

Blood (2021) 138 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2021-155018

Published: 2021

Journal Articles

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Blood (2021) 138 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2021-144508

Published: 2021

Journal Articles

Genotype-Phenotype Relationship Among 1200 Unrelated White Patients with Inherited FVII Deficiency: A Three-Center Database Study

Susan Halimeh, Gili Kenet, Piotr Kuta, Maria Shneyder, Tido Bajorat, Ulrike Nowak-Göttl

Blood (2021) 138 (Supplement 1): 589.

https://doi.org/10.1182/blood-2021-153580

Published: 2021

Journal Articles

The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Assaf Arie Barg, Gili Kenet, Tami Livnat, Einat Avishai, Ivan Budnik, MDPhD, Tami Brutman-Barazani, Ilia Tamarin, Aharon Lubetsky, Dalia Bashari, Rima Dardik, PhD, Shadan Lalezari, Mudi Misgav

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-138777

Published: 2020

NARROW

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Real World Data of Extended Venous Thromboembolism Prophylaxis with Low Dose Apixaban Following Cancer Associated Thrombosis

rAAV8-PC Gene Therapy for Severe Protein C Deficiency Using a Novel Murine Model

Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7

Intravenous 3K3A-Activated Protein C Inhibits Murine Ocular Inflammation and Suppresses Ocular Choroidal Neovascularization

Pediatric Splenic Infarcts - a 10-Year Retrospective Study

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Pediatric Splanchnic Vein Thrombosis: Systematic Review and Meta-Analysis

Venous Thromboembolism in Children, Adolescents and Young Adults: Findings from the Riete Registry

Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

The Immunogenicity, Safety and Efficacy of N8-GP in Previously Untreated Patients (PUPs) with Severe Hemophilia A: pathfinder6 End-of-Trial Results

Fitusiran Prophylaxis Improves Health-Related Quality of Life in People with Hemophilia a or B, with or without Inhibitors: Results of ATLAS-PPX Study

Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Genotype-Phenotype Relationship Among 1200 Unrelated White Patients with Inherited FVII Deficiency: A Three-Center Database Study

The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only